Abstract. Chemotherapy (CT) resistance in ovarian cancer is broad and encompasses diverse, unrelated drugs, suggesting more than one mechanism of resistance. We aimed to analyze the gene expression patterns in primary serous epithelial ovarian cancer (EOC) samples displaying different responses to first-line CT in an attempt to identify specific molecular signatures associated with response to CT. Initially, the expression profiles of 15 chemoresistant serous EOC tumors [time to recurrence (TTR) ≤6 months] and 10 chemosensitive serous EOC tumors (TTR ≥30 months) were independently analyzed which allowed the identification of specific sets of differentially expressed genes that might be functionally implicated in the evolution of the chemoresistant or the chemosensitive phenotype. Our data suggest that the intrinsic chemoresistance in serous EOC cells may be attributed to the combined action of different molecular mechanisms and factors linked with drug influx and efflux and cell proliferation, as possible implications of other molecular events including altered metabolism, apoptosis and inflammation cannot be excluded. Next, gene expression comparison using hierarchical clustering clearly distinguished chemosensitive and chemoresistant tumors from the 25 serous EOC samples (training set), and consecutive class prediction analysis was used to develop a 43-gene classifier that was further validated in an independent cohort of 15 serous EOC patients and 2 patients with other ovarian cancer histotypes (test set). The 43-gene predictor set properly classified serous EOC patients at high risk for early (≤22 months) versus late (>22 months) relapse after initial CT. Thus, gene expression array technology can effectively classify serous EOC tumors according to CT response. The proposed 43-gene model needs further validation.
Introduction
Ovarian cancer is responsible for more cancer deaths among women in the Western world than all other gynecologic malignancies (1) . If not detected early, this disease has a 5-year survival rate of <20%. Epithelial carcinoma of the ovary is characterized by presentation at an advanced stage, spreads primarily by an intraperitoneal route, and relative sensitivity to CT. An initial surgical approach is essential for aggressive cytoreduction and proper staging of the disease process, which in turn improves response to CT and survival (2) . CT has had an increasingly important role in the effective treatment of ovarian cancer. Combination CT with paclitaxel (taxol) plus a platinum compound (carboplatin or cisplatin) is the current regimen of choice for the treatment of advanced EOC (3) . A number of clinical issues, however, are unresolved including drug dosage and schedule, duration of treatment, and route of administration (4) . Indeed, although significant proportions of women respond to CT, the majority of responders (~60-75%) eventually relapse and die from recurrent disease (5) (6) (7) (8) . CT resistance in ovarian cancer is broad and encompasses diverse, unrelated drugs, suggesting more than one mechanism of resistance. A number of cellular factors have displayed increased expression and activity in drug-resistant ovarian cancer lines and/or tumor tissues (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , but consecutive in vivo studies have failed to assess their clinical importance and to translate them into recommendations for specific therapies or prognosis in ovarian cancer patients (19) (20) (21) .
To avoid unnecessarily subjecting a patient to the side effects of anticancer drugs, it is a matter of urgency to understand the molecular mechanisms of drug resistance and to establish a diagnostic method to determine sensitivity to CT in patients with advanced ovarian cancer. Recent advances in expression genomics through global transcript analysis have led to the molecular classification of cancers (22) (23) (24) (25) and the prediction of outcome and treatment response (26) (27) (28) (29) .
In the present study, gene expression patterns were analyzed in primary tumor samples obtained upon surgery from patients with advanced serous EOC in an attempt to identify specific molecular signatures of serous EOC tumors according to their response to initial CT. The initial group comprised 15 resistant tumors from patients with progressive disease under CT or displaying recurrence in the first 6 months, and 10 sensitive tumors from patients with a TTR of at least 30 months. These conservative clinical criteria for defining first-line platinum sensitivity and resistance were employed to exclude tumors with intermediate levels of resistance. The serous EOC histotype was chosen because serous adenocarcinomas represent the most frequent type (~80%) of EOC (30, 31) . Moreover, we wanted to use a more homogeneous set of tumor samples for our gene expression analyses, since different ovarian cancer histotypes display distinct expression patterns (32) . First, the expression profiles of all 25 serous EOC tumors were independently analyzed which allowed the identification of specific sets of differentially expressed genes that might be functionally implicated in the evolution of the chemoresistant or the chemosensitive phenotype. Next, by performing gene expression comparison of the 25 primary chemosensitive and chemoresistant serous EOC tumors we were able to clearly distinguish chemosensitive and chemoresistant tumors from the 25 serous EOC samples by hierarchical clustering, and to consecutively identify a 43-gene classifier that was further tested in an independent cohort comprising 15 serous EOC tumors, one clear cell carcinoma and one endometrioid carcinoma. Our results provide the basis for extended study to further refine our predictor gene set which could help to overcome drug resistance and ameliorate ovarian cancer treatment.
Materials and methods
Patients and tissue specimens. Primary cancer tissues were obtained for expression profiling analysis prior to initial CT from 40 patients with invasive serous papillary adenocarcinoma of the ovary (FIGO stage IIIC and IV, grade 2 and 3) at the Hotel-Dieu de Quebec Hospital, Quebec, Canada. The patients received CT following debulking surgery between 1998 and 2003. All tumors were histologically classified according to the criteria defined by the World Health Organization. The CT treatment was completed for all patients and the response to treatment was evaluated following the RECIST group guidelines (33) . Time to recurrence (TTR) was added as a supplementary variable, defined as the time interval between the last cycle of the initial CT regimen and recurrence.
The 25 serous EOC patients initially included in the study were formally divided into two groups based on response to CT. The sensitive group (1S-10S) showed a TTR of at least 30 months, while in the resistant group the disease progressed under CT or during the first 6 months following CT (TTR ≤6 months) (Table IA) . These 25 patients were further used for predictor marker discovery (training set), and an additional 15 serous EOC patients were analyzed as an independent validation set (test set). Two patients with different histological subtypes of ovarian cancer (one patient with clear cell carcinoma and one patient with endometrioid carcinoma) were also included in the test set (Table IB) .
Tumor tissue from all patients was snap-frozen in liquid nitrogen within 1 h after surgery. A control section was cut from the bloc and stained with H&E, in order to assess the percentage of tumor tissue; only samples with >70% of tumor cells were selected. The study was approved by the Clinical Research Ethics Committee of the Hotel-Dieu de Quebec Hospital and all patients gave informed consent for voluntary participation.
Gene expression analysis. Gene expression analysis was carried out as previously described (34) . Briefly, fluorescently labeled cRNA targets were generated from 0.5 μg of total RNA in each reaction using a fluorescent linear amplification kit (Agilent) and 10.0 mM Cyanine 3-or 5-labeled CTP (PerkinElmer, Boston, MA), following the user's manual. Labeled cRNAs were purified using the RNeasy mini kit (Qiagen) and applied to the Human 1A (v2) oligonucleotide microarray (Agilent), containing 20,174 genes. One microgram of cyaninelabeled cRNA from one ovarian tumor was mixed with the same amount of reverse-color cyanine-labeled cRNA from a pool, which contained equal amounts of each RNA from the 25 serous EOC patients included in the training set. Array hybridization, washing, scanning and data extraction were performed as previously described (34) . GeneSpring software (Agilent) was used to generate lists of selected genes and for different statistical and visualization methods, as described previously (34) . Additionally, class prediction analysis was performed to predict the value, or 'class', of an individual parameter in an uncharacteristic sample or set of samples. Classification was generated by the 'Support Vector Machines' algorithm of GeneSpring using the training set and the test set for the parameter 'Response to initial CT'. Fisher's exact test method was used to select the predictor set of genes.
Semi-quantitative RT-PCR (sqRT-PCR).
Validation of microarray data was performed for selected differentially expressed genes by sqRT-PCR as previously described (34) . Upon analysis of the microarray data, we found that the tumor-differentially expressed 1 (TDE1) gene displayed no change in expression levels in all tumor samples analyzed and was used as an internal standard. Primers were designed for these loci with the sequences freely available from the Entrez Nucleotide database and the Primer3 algorithm for primer design (http://www-genome.wi.mit.edu/cgi-bin/primer/ primer3_www.cgi).
Results
Gene expression signatures of primary chemoresistant and chemosensitive tumors. The clinicopathological characteristics of the patients included in this investigation are presented in Table I . In our initial study, we included tumors from 25 serous EOC patients (comprising our training set; Table IA) ; the tumors were either grade 2 or 3, stage IIIC and IV according to FIGO (International Federation of Obstetrics and Gynecology). All 25 patients had maximal debulking surgery, with residual disease of no more than 2 cm. In the good responders (chemosensitive) group (1S to 10S), 3 patients had a minor histology component of endometrioid, clear cell and squamous histotype respectively. In this group were 
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10 patients with a TTR interval of ≥30 months. The poor responders (chemoresistant) group (1R to 15R) comprised 15 patients with progressive disease under CT (in this case we assigned a TTR value of 0 months) or in the first 6 months following CT. Twenty patients received 6 cycles of combined CT based on a platinum compound (cisplatin or carboplatin) and taxol, and 5 patients received a platinum compound and cyclophosphamide. The median age for the chemoresistant group was 62 (range, , and the median age for the chemosensitive group was 57 (range, 53-77).
A reference RNA pool was made by mixing equal amounts of total RNA from all 25 serous EOC samples from the training set and the gene expression pattern of each tumor sample was compared to the pooled sample. Two hybridizations were carried out for every tumor against the reference sample using a fluorescent dye reversal (dye-swap) technique.
First, we separately evaluated the gene expression profiles of the chemoresistant and the chemosensitive serous EOC tumors in search for specific markers and/or molecular mechanisms that could determine the chemoresistant or the 
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chemosensitive phenotype. For each of the two groups, a subset of differentially expressed genes was selected by initial filtering on confidence at p=0.001, followed by filtering on expression level (≥2-fold). Using these stringent selection criteria, we found 230 genes to be down-regulated and 60 genes to be up-regulated specifically in the chemoresistant group, while 163 genes were down-regulated and 20 genes were up-regulated specifically in the chemosensitive group. Notably, those down-regulated in the chemoresistant serous EOC tumors included a substantial number of genes implicated in cellular proliferation and cell cycle control, cell adhesion, membrane transport, as well as some genes involved in tumor (including ovarian tumor) suppression, DNA repair, apoptosis, and representing antagonists of the neoplastic phenotype (Table IIA) . Several markers, known to be associated with ovarian malignancy and tumor progression, as well as genes implicated in cell migration and invasion, inflammation and chemoresistance were overexpressed in the chemoresistant samples (Table IIB) . Down-regulated genes in the chemosensitive serous EOC tumors included numerous genes known to enhance tumor (including ovarian tumor) progression and invasion, ovarian and other tumor markers, genes involved in lipid metabolism and transport, inflammation, as well as several oncogenes (Table IIC) .
Gene expression differences between primary chemoresistant and chemosensitive tumors. Next, we evaluated whether intrinsically chemoresistant and chemosensitive serous EOC tumors could be distinguished based on their gene expression profiles. We compared the expression data in all 25 tumors from the training set in search of discriminatory genes. First, we selected a subset of candidate genes by filtering on signal intensity (2-fold) to eliminate genes with uniformly low expression or genes whose expression did not vary significantly across the samples, retaining 377 genes. One-way ANOVA parametric test (Welch's t-test; variances not assumed equal) Table III . Predictor set of 43 genes differentially expressed between ovarian cancer patients who displayed sensitivity (TTR >22 months) or resistance (TTR ≤22 months) to first-line chemotherapy. was further used to select discriminatory genes. t-test with p-value cutoff of 0.01 selected 155 genes for which expression differed in primary sensitive and resistant tumors. Clustering analysis based on the 155-genes list was performed using the standard Condition Tree algorithm provided in GeneSpring and revealed the formation of two major cluster groups that perfectly correspond with response to initial CT treatment (Fig. 1) . The 155-genes list is presented in Supplementary  Table I. The 155 genes differently expressed at p-value cutoff of 0.01 were up-regulated or down-regulated at least 2-fold in chemoresistant tumors in comparison with chemosensitive tumors. Functional classes of these differently expressed genes mainly include metabolism (30%), cell growth and maintenance (18%), signal transduction (12%), immune response (12%), cell organization and biogenesis (11%), transport (9%) and apoptosis (3%); the remainder (5%) have unknown functions.
Fifty-three genes from the 155-genes list were up-regulated in chemoresistant tumors. Major classifications of these genes include signal transduction, metabolism, cell growth and maintenance and immune response. Notably, ~22% of all up-regulated genes in resistant tumors are associated with inflammatory and immune responses (including chemokine C-C and C-X-C motif ligands, several serum amyloid A family members and prostaglandin D2 synthase). Genes downregulated in resistant tumors (102 genes) are mainly involved in metabolism, cell growth and maintenance, cell organization and biogenesis.
Cross-validation of the training set. Next, we cross-validated the 25 tumor samples of the training set in an attempt to identify the minimal list of genes that can correctly classify the tumor samples from this set as chemoresistant or chemosensitive. Classification was generated using the 'Support Vector Machines' algorithm of the class prediction analysis of GeneSpring. The 25 serous EOC tumor samples were cross-validated for the parameter 'Response to initial CT'. We began validation analysis using an expanded gene list of all 1.4-fold filtered (2,514) genes to avoid selection bias (35, 36 ). Fisher's exact test method was used to select the minimal gene number with perfect class prediction score. Using this analysis we identified a 43-gene predictor gene set (Table III) that correctly classified all primary sensitive and resistant tumors included in the training set (Table IA) .
Confirmation of the expression measurements.
To confirm measurement of RNA concentrations, expression values derived from adjusted Agilent data were correlated with values from sqRT-PCR for 21 variably expressed genes (Table IV) . Validation of differential gene expression was performed for selected genes from the 43-gene predictor set (ACAT2, ALDH9A1, PTGDS, LDHB, RBBP7, TOPK), as well as from a number of genes that were down-regulated (GSTA1, HSPE1, NDUFB3, SCGB2A1, CTSL2, ASNS, PRSS2, BMO39 SDHC) or up-regulated (ECGF1, APOE, CD36, FOSB) in the resistant serous EOC tumors, as well as 2 genes (HBB, SAA1) that were down-regulated in the sensitive serous EOC group. Mean expression values were positive for all 21 genes and significantly positive (p≤0.05) for 13 of 21 genes.
Validation in an independent cohort (test set)
. Consecutively, 15 serous EOC patients that exhibited more diverse TTR values ranging between 0 and ≥50 months were used as a test set for the validation of the predictive limits of the 43-gene Table III . Continued.
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classifier. Fourteen patients had serous EOC, stage IIIC or IV, grade 2 or 3; one patient had serous EOC stage IIIB grade 3. The median age was 66 years (range 44-86). After debulking surgery, the patients received 6 cycles of CT with a platinum compound and taxol (14 cases) or a platinum compound and cyclophosphamide (1 case). In a preliminary attempt to validate our selected predictor gene list in other histotypes of ovarian cancer, we have also included in the test set one patient with clear cell carcinoma stage IIIC and one patient with endometrioid carcinoma stage IIA, grade 3. The clinical characteristics of all 17 patients from the test set are shown in Table IB . The gene expression pattern of each tumor sample of the test set was compared to that of the pooled reference sample used for cross-validation of the training set. All serous EOC patients from the test set displaying TTR values of ≤22 months were classified as resistant to first-line CT treatment with the exception of one serous EOC patient with TTR of 21 months that was classified as sensitive, while the serous EOC patients with TTR ≥30 months were classified as sensitive. The two additional patients with different histological subtypes of ovarian cancer (TTR values of 0 and 12 months, respectively) were correctly classified as resistant with our 43-gene predictor set. All data from the validation analysis of the test set are presented in Table IB .
Discussion
In the present study, we initially analyzed the gene expression profiles in primary tumor samples of 10 serous EOC patients that displayed a good response to CT (TTR ≥30 months) and 15 serous EOC patients with a poor response to CT (TTR ≤6 months, aiming to discover specific factors or mechanisms that determine response to first-line treatment and/or disease progression. The majority of these patients were treated postoperatively with a platinum compound and taxol; five patients were treated with carboplatin and cyclophosphamide (Table IA) . Our goal was to determine the profile of two definite groups of tumors with different responses to CT, and to identify those genes that best distinguish the two groups. For this reason, we chose to use a pool of equal amounts of total RNA from each tumor as reference RNA. This has two advantages: firstly, it maximizes differences among tumor samples; and secondly, it ensures accurate quantification of expression levels for genes that are not expressed or are expressed at very low levels in a universal reference sample (56) . Moreover, a pooled reference design is preferable when the major goal of a microarray experiment represents clustering and class prediction analysis (57) .
Serous EOC displayed distinctive gene expression according to their response to CT. Thus, different genes implicated Table IV . Correlation of mRNA expression data from the training set with sqRT-PCR derived values.
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in tumor and neoplastic phenotype suppression, cell adhesion and apoptosis were down-regulated in the resistant tumor serous EOC samples (Table IIA) . Interestingly, the expression of numerous genes representing positive regulators of cell proliferation was suppressed in the resistant serous EOC tumors (Table IIA) , which supports the concept of ours and others that a decreased proliferation state may be involved in the development of acquired chemoresistance (34, (58) (59) (60) (61) (62) . Down-regulated genes in the resistant group also comprised different membrane transporters and channels including amino acid (SLC3A1), nucleoside (SLC25A4) and folate transporters (FOLR1), Ca 2+ channels and binding proteins (CACNA2D3, S100A2), and different ion transporters and channels (KCNJ16, SLC26A9, SLC9A9). Multiple types of membrane transporters and channels play important roles in sensitivity and resistance to anticancer drugs (63) . Thus similar to our findings, the suppression of the S100A2 gene was previously associated with chemoresistance (64) . Moreover, it was demonstrated that solute carrier (SLC) transporters, such as folate, nucleoside, and amino acid transporters, commonly increase chemosensitivity by mediating the cellular uptake of hydrophilic drugs, and the expression of different sodium, chloride, potassium, and other ion channels correlated with drug sensitivity and activity (65) . Hence, the suppressed expression of the above transporter genes may contribute to the chemoresistant serous EOC phenotype. On the contrary, one member (ABCA7) of the ABC transporter family known to confer drug resistance by enhancing drug efflux (63, 65) , was up-regulated in the chemoresistant serous EOC tumors. Overexpressed genes in the resistant group also included various genes implicated in ovarian malignancy and tumor progression, cell migration/ invasion and inflammation (Table IIB) . These data confirm our recent findings that genes functionally involved in mechanisms of chemoresistance and ovarian tumor progression are commonly upregulated in post-CT (chemoresistant) ovarian tumors (34) .
The sensitive serous EOC phenotype was mainly characterized by the suppression of different genes known to be functionally involved in disease progression, including genes responsible for tumor invasion, inflammatory mediators, various tumor markers and some oncogenes (Table IIC) . The observed down-regulation of several oncogenes (MYCN, NPM2, RAS-D2, RAD9A; Table IIC) may additionally support the sensitive phenotype since elevated transcription of some oncogenes including c-Myc and Ras has been previously linked to multidrug resistance (66) (67) (68) . In sensitive tumors, we have also monitored the down-regulation of different genes involved in control of lipid metabolism and transport. Indeed, enhanced lipid and protein degradation is a common finding among cancer patients. Alterations in the serum lipolytic activity of cancer patients correlate with response to therapy as patients who showed a positive response to CT also showed a decrease in their plasma levels of lipolytic activity (69) . Ovarian cancer patients exhibit altered lipid metabolism and the degree of these alterations has been previously linked with response to therapy, as these metabolic alterations may influence disease outcome (70) . Our data suggest that lower lipid metabolism rates might improve treatment response in serous EOC patients.
As a further step in the analysis of our initial data (training) set, we first looked for gene expression patterns that could discriminate good from poor responders upon initial CT of serous EOC patients. Clustering analysis, based on a set of 155 discriminatory genes, accurately distinguished primary serous EOC tumors according to their response to CT (Fig. 1) . Fifty-three of these genes were overexpressed in the treatment-resistant cluster with major categories including immune and inflammatory response, regulation of transcription and hemoglobin synthesis. These results are not unexpected since: a) different inflammatory mediators, which play diverse roles such as inducing angiogenesis, invasion, autocrine growth loops and resistance to apoptosis, are shown to be elevated in ovarian carcinoma (71); b) some of the overexpressed transcription regulators (FOSB, FOS, NR4A1, NR4A2 and NR4A3) are shown to be associated with cancer progression and invasion (72, 73) ; c) Hb-· and Hb-ß were recently characterized as ovarian cancer biomarker proteins (74) . Of the 102 genes overexpressed in the good response group, major categories were signal transduction, metabolism, regulation of transcription and nucleosome assembly (almost all histone genes); cell cycle regulation, cell adhesion, cytoskeleton structure, transport and apoptosis. In sensitive tumors, genes involved in cell cycle control (e.g., overexpression of CDCA1, CDCA7, BIRC5, BUB1 and CKS2) and apoptosis (e.g., overexpression of Siva and PDCD5) seem to contribute to sensitivity to CT. Differences in RNA expression were confirmed by sqRT-PCR for a sample of genes.
Next, an additional statistical approach (class prediction analysis) was applied to specifically search for the minimal set of genes that could predict response to first-line CT. This led to the identification of a 43-gene predictive model that correctly classified all 25 tumors based on response to initial CT. Our predictor model was subsequently validated in an independent cohort of 15 serous EOC patients and 2 patients with other ovarian cancer histotypes. The 43-gene model classified most serous EOC tumors with TTR ≤22 months as resistant to first-line CT, with the exception of one serous EOC tumor with TTR of 21 months that was classified as sensitive. The serous EOC tumors with TTR ≥30 months were classified as sensitive. Thus according to our predictive method, the 21-to 22-month TTR interval may represent the turning point for our 43-gene predictor in classifying women with advanced serous EOC destined for early (TTR ≤22 months) or late (TTR >22 months) relapse following CT treatment. Indeed, this transition period coincides with the literature data for median progression-free survival (20-22 months) of ovarian cancer patients with optimally debulked advancedstage disease treated with platinum-paclitaxel (75, 76) . Similarly, a 14-gene predictive model for treatment outcome in ovarian cancer was previously developed (75) that could discriminate women at high risk for early (≤21 months) versus late (>21 months) relapse after initial CT. Furthermore, the fact that one clear cell carcinoma patient and one endometrioid carcinoma patient (TTR values of 0 and 12 months respectively) were both correctly classified as resistant with our 43-gene model, as well as the presence in the training set of three patients with mixed histotypes, is indicative for the possible application of our predictor set in other ovarian cancer histotypes.
Our 43-gene classifier list does not include many genes that have been implicated in drug resistance based on studies in model systems but, rather, identifies expression patterns of genes that could be used as a predictive test for response to CT. In this regard, the present results additionally parallel those of Hartmann et al, who identified a gene expression profile in ovarian cancer patients that correlated with drug sensitivity and treatment outcome but also contained a paucity of transcripts commonly implicated in resistance (77) . It is provocative to speculate on the biologic function of the 43 genes that form our current predictor. Indeed, many of these genes need not have a proximal role in the biologic function that they predict. They may be robust but distant downstream transcriptional effects of biologic events that influence drug sensitivity. Furthermore, informative gene lists can change substantially as the training set size from which they are generated increases. The rank order of genes is particularly susceptible to change from one list to another. Therefore, from the vantage point of gaining mechanistic insight into the biology of CT sensitivity or resistance, these results should be regarded as hypothesis-generating only. However, it was encouraging to see that different genes in our marker set of 43 have been shown previously to be involved in disease progression (TOPK, PTGDS, LDHB, RBBP7, NDUFB4, ACADVL, ALDH9A1, ACAT2, GPR49), apoptosis (PSMD1, Siva, P53CSV, HSPA4), or response to treatment (PSMD14, NDUFB4, CCT6A, ALDH9A1) in different cancer types including ovarian carcinoma (see Table III for details). It is interesting to note that some of the above listed and several other genes from our predictive gene list are involved in the regulation of cellular proliferation or cell cycle control (TOPK, PTGDS, WDR12, HCAP-G, BOLA3, RBBP7, CDCA2, ADO24, BRRN1) which supports once more the concept that the modulation of the cellular proliferative rate could be determinative for CT response (34, (56) (57) (58) (59) (60) .
Several recent studies have used gene expression profiling to predict disease prognosis and survival (78, 79) and response to CT (62, 77, 80, 81) in ovarian cancer patients. These studies have identified different prognostic and predictor gene sets which can distinguish early from late relapse or disease progression; however, no significant overlap was found between the individual predictor lists. Our 43-gene predictor set also does not display any evident similarity with the predictor sets identified so far. These differences could be due to several reasons including various criteria of patient selection and the utilization of different gene expression platforms (nylon cDNA arrays, Affymetrix chips, Agilent oligonucleotide microarrays). Additionally, our analysis was based mostly on primary serous EOC tumors, while the other groups have used mixed histotypes of ovarian tumors, including recurrent and metastatic tumors. Although all of these studies, including ours, suggest that gene expression profiling is capable of defining prognosis and response to treatment, additional validation is required to determine the ultimate value of this approach in clinical practice. Also, combining the different predictor gene sets, while posing challenging informatics problems, might be much more informative.
In conlusion, gene expression profiling could discriminate serous EOC tumors according to their response to CT. Our data suggest that the intrinsic chemoresistance in serous EOC cells may be attributed to the combined action of different molecular mechanisms and factors linked with drug influx and efflux and cell proliferation, as the possible implications of other molecular events, including altered metabolism, apoptosis and inflammation, cannot be excluded. We have additionally developed a 43-gene classifier model that predicts early or late relapse to first-line CT in patients with advanced ovarian serous adenocarcinomas. Our data lend support to the suggestion that gene expression array technology can effectively classify serous EOC tumors according to response or resistance. To ultimately define the molecular portrait of ovarian cancers sensitive or resistant to first-line CT, these results should be validated in a study with a large prospective cohort including patients with different histological types of ovarian cancer. Further patient recruitment and analysis will refine the predictor gene list for classifying tumors based on response to initial therapy. This type of molecular profiling could have important clinical implications in resolving chemoresistance and defining the optimum treatment for an individual patient, thus reducing the use of unproductive treatments, unnecessary toxicity, and overall cost.
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